Ivan Poullaos
Partner
Ivan is an accomplished patent trial lawyer with experience in many areas of technology, but particular experience in the life sciences sector representing pharmaceutical companies in biologics and Hatch-Waxman patent infringement cases. Chambers USA recognized Ivan as an “Up and Coming Practitioner” for intellectual property, noting that he “is an extremely responsive and trial-savvy lawyer.”
Key Matters
Achieved a notable trial win for a generic pharmaceutical company by convincing the court to invalidate the patent covering the active ingredient molecule in the Hepatitis B treatment, Baraclude® (entecavir). The decision was especially important because, for the first time, it invalidated as “obvious” a patent on a new chemical compound. The case received extensive press coverage, including articles in Forbes, Bloomberg, Law360, Inside Counsel, and countless IP, FDA, and patent law-related blogs. Ivan also represented this client in the appellate stage of the case, where the district court’s ruling was affirmed.
Achieved a pharmaceutical trial victory in a case in which the court invalidated the patent on the Testim® (testosterone gel) product.
Ivan’s other noteworthy life sciences patent cases have included:
- Representation of a major cell culture device manufacturer regarding cell culture technology and methods;
- The COVID vaccine and its delivery mechanism;
- The anticancer treatments Clolar® (clofarabine), Faslodex® (fulvestrant), Temodar® (temozolomide), and Gilotrif® (afatinib);
- The opioid dependence treatment products Zubsolv®, Suboxone® tablets, and Subutex® tablets (buprenorphine and buprenorphine/naloxone);
- The pain relief products Lidoderm® (lidocaine patch), Exalgo® (hydromorphone HCl), and Abstral® (fentanyl sublingual tablets);
- The IBS (peptide) drug Linzess® (linaclotide);
- The antibiotics Omnicef® (cefdinir), and Dificid® (fidaxomicin);
- The nasal steroid drug Veramyst® (fluticasone furoate);
- The dementia treatment Exelon® (rivastigmine);
- The prostate treatment Avodart® (dutasteride);
- The estrogen modulator Evista® (raloxifene);
- The low testosterone treatments Fortesta® (testosterone gel) and Testim® (testosterone gel); and
- The diabetes and weight loss drugs Tradjenta® (linagliptin), Jentadueto® (linagliptin/metformin), and Qsymia® (phentermine/topiramate).
Ivan’s experience also includes a broad range of commercial, mechanical, and high-tech patent cases. For example, Ivan has represented:
- A worldwide leader in IT and networking in matters involving virtual private network (VPN) tunneling;
- Two leading high-tech companies in cases involving video processing technology and tablet computers;
- A financial technology firm in a patent infringement case involving software for electronic futures trading;
- A telecommunications firm in patent cases involving mobile telecommunications data networks and voice-over-IP systems;
- One of the world's leading technology companies in a suit relating to the development of its first smartphone;
- A defense firm in a patent case involving a “rolling code” security software algorithm;
- A railcar manufacturer in a patent case concerning gondola rail car designs;
- An agribusiness company in a mechanical patent case involving an enclosed belt conveyor; and
- A global automotive parts company in counseling concerning patents on brake rotors and brake pads.
Poullaos harnesses his chemistry acumen to craft compelling trial strategies, earning renown for his courtroom successes and innovative approach.
IAM Patent 1000